Geode Capital Management’s Aptevo Therapeutics APVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-10,821
| Closed | -$48K | – | 4389 |
|
|
2026
Q2 | $48K | Sell |
10,821
-2,516
| -19% | -$12.1K | ﹤0.01% | 4255 |
|
|
2026
Q1 | $56.9K | Buy |
+13,337
| New | +$91.2K | ﹤0.01% | 4282 |
|
|
2025
Q2 | – | Sell |
-29
| Closed | -$12.2K | – | 4449 |
|
|
2025
Q1 | $12.2K | Buy |
+29
| New | +$36.7K | ﹤0.01% | 4422 |
|
|
2024
Q4 | – | Sell |
-3
| Closed | -$7.85K | – | 4475 |
|
|
2024
Q3 | $7.85K | Buy |
3
+2
| +200% | +$9.21K | ﹤0.01% | 4495 |
|
|
2024
Q2 | $5.93K | Buy |
+1
| New | +$14.9K | ﹤0.01% | 4569 |
|
|
2024
Q1 | – | Hold |
0
| – | -$7.82K | – | 4610 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 4607 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 4581 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 4408 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 4316 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 4321 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 4327 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 4301 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 4168 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 4280 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 3930 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 3676 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 3514 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 3362 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 3946 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 3879 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 3964 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 3980 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 3981 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 3901 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 3891 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 3767 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 3409 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 3401 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 3551 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 3436 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 3643 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 3686 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3559 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3500 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3503 |
|
Other funds holding APVO
Geode Capital Management's APVO Position: Q3 2026 in Review
Geode Capital Management sold out of Aptevo Therapeutics (APVO) in Q3 2026, closing a stake of 10,821 shares — an estimated $48K sold.
Geode Capital Management first reported a position in APVO in Q2 2024 and held it in 5 quarters. The position peaked at $56.9K in Q1 2026. 2 funds tracked by Wall St. Rank hold APVO as of Q3 2026.
- Geode Capital Management reported no remaining Aptevo Therapeutics position as of Q3 2026 after selling out during the quarter.
- Geode Capital Management sold 10,821 Aptevo Therapeutics shares in Q3 2026, an estimated $48K.
- Geode Capital Management first reported a position in Aptevo Therapeutics in Q2 2024 and held it in 5 quarters.
- Geode Capital Management's Aptevo Therapeutics position peaked at $56.9K in Q1 2026.
- 2 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.